The stock of Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a huge mover today! About 145,760 shares traded hands or 267.83% up from the average. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has declined 12.24% since March 7, 2016 and is downtrending. It has underperformed by 19.83% the S&P500.
The move comes after 8 months negative chart setup for the $28.36 million company. It was reported on Oct, 10 by Barchart.com. We have $2.81 PT which if reached, will make NASDAQ:PRAN worth $3.97 million less.
According to Zacks Investment Research, “Prana Biotechnology was established to commercialize research into Alzheimer’s disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana’s technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.”
More notable recent Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) news were published by: Marketwatch.com which released: “Prana Biotechnology Ltd. ADR” on November 16, 2010, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on February 11, 2011, Fool.com published: “Why Prana Biotechnology Limited and Medbox Inc. Lost Big Today” on February 19, 2014. More interesting news about Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) were released by: Fool.com and their article: “Down 70%: Is Prana Biotechnology Ltd. a Buy?” published on March 31, 2014 as well as Investorplace.com‘s news article titled: “6 Biotechnology Stocks to Sell Now” with publication date: October 10, 2016.
PRAN Company Profile
Prana Biotechnology Limited (Prana), incorporated on November 11, 1997, is an Australia development stage medical biotechnology Company. The Firm is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimerâ€™s and Huntington’s diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.